Novel treatment strategies for aggressive non-Hodgkin’s lymphoma

Bibliography

• LEVITT M, MARSH JC, DECONTI RC et al.: Combination sequential chemotherapy in advanced reticulum cell sarcoma. Cancer (1972) 29:630-636.
   PubMed Web of Science ®Google Scholar
• MCKELVEY EM, GOTTLIEB JA, WILSON HE et al.: Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer (1976) 38:1484-1493.
   PubMed Web of Science ®Google Scholar
• MILLER TP, JONES SE: Chemotherapy of localised histiocytic lymphoma. Lancet (1979) 1:358-360.
   PubMed Web of Science ®Google Scholar
• MILLER TP, JONES SE: Initial chemotherapy for clinically localized lymphomas of unfavorable histology. Blood (1983) 62:413-418.
   PubMed Web of Science ®Google Scholar
• CABANILLAS F, BODEY GP, FREIREICH EJ: Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types. Cancer (1980) 46:2356-2359.
   PubMed Web of Science ®Google Scholar
• CONNORS JM, KLIMO P, FAIREY RN, VOSS N: Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann. Intern. Med. (1987) 107:25-30.
   PubMed Web of Science ®Google Scholar
• MILLER TP, DAHLBERG S, CASSADY JR et al.: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N. Engl. J. Med. (1998) 339:21-26.
   PubMed Web of Science ®Google Scholar
• SPIER CM, LEBLANC M, CHASE EM, FISHER RI, MILLER TP: Histologic subtypes do not confer unique outcomes in early-stage lymphoma: long-term follow-up of SWOG 8736. Blood (2004) 104:3263.
   Google Scholar
• HORNING SJ, WELLER E, KIM K et al.: Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484. J. Clin. Oncol. (2004) 22:3032-3038.
   PubMed Web of Science ®Google Scholar
• FISHER RI, MILLER TP, O’CONNOR OA: Diffuse aggressive lymphoma. Hematology (Am. Soc. Hematol. Educ. Program) (2004):221-236.
   PubMedGoogle Scholar
• COIFFIER B: Treatment of diffuse large B-cell lymphoma. Curr. Hematol. Rep. (2005) 4:7-14.
   PubMedGoogle Scholar
• MILLER TP, UNGER JM, SPIER CM et al.: Effect of adding rituximab to three cycles of CHOP plus involved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG-0014). Blood (2004) 104:158.
   Google Scholar
• COIFFIER B: State-of-the-art therapeutics: diffuse large B-cell lymphoma. J. Clin. Oncol. (2005) 23:6387-6393.
   PubMed Web of Science ®Google Scholar
• COIFFIER B, LEPAGE E, BRIERE J et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. (2002) 346:235-242.
   PubMed Web of Science ®Google Scholar
• SEHN LH, DONALDSON J, CHHANABHAI M et al.: Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J. Clin. Oncol. (2005) 23:5027-5033.
   PubMed Web of Science ®Google Scholar
• PFREUNDSCHUH M, TRUMPER L, KLOESS M et al.: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood (2004) 104:634-641.
   PubMed Web of Science ®Google Scholar
• PFREUNDSCHUH M, TRUMPER L, KLOESS M et al.: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood (2004) 104:626-633.
   PubMed Web of Science ®Google Scholar
• PFREUNDSCHUH M, KLOESS M, SCHMITS et al.: Six, not eight, cycles of bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with DLBCL. Results of the RICOVER-60 trial of the German NHL study. Blood (2005) 106:13.
   Google Scholar
• WILSON WH, GROSSBARD ML, PITTALUGA S et al.: Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood (2002) 99:2685-2693.
   PubMed Web of Science ®Google Scholar
• GUTIERREZ M, CHABNER BA, PEARSON D et al.: Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J. Clin. Oncol. (2000) 18:3633-3642.
   PubMed Web of Science ®Google Scholar
• WILSON WH, PORCU P, HURD D et al.: Phase II study of dose-adjusted EPOCH-R in untreated de novo CD20+ diffuse large B-cell lymphoma (DLBCL)-CALGB 50103. J. Clin. Oncol. (2005) 23:6530.
   Google Scholar
• PRO B, YOUNES A: New molecular targets for treatment of lymphoma. Curr. Oncol. Rep. (2004) 6:360-368.
   PubMedGoogle Scholar
• YOUNES A, KADIN ME: Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J. Clin. Oncol. (2003) 21:3526-3534.
   PubMed Web of Science ®Google Scholar
• ASHKENAZI A: Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer (2002) 2:420-430.
   PubMed Web of Science ®Google Scholar
• BHARDWAJ A, AGGARWAL BB: Receptor-mediated choreography of life and death. J. Clin. Immunol. (2003) 23:317-332.
   PubMedGoogle Scholar
• EMERY JG, MCDONNELL P, BURKE MB et al.: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. (1998) 273:14363-14367.
   PubMed Web of Science ®Google Scholar
• DEGLI-ESPOSTI M: To die or not to die-the quest of the TRAIL receptors. J. Leukoc. Biol. (1999) 65:535-542.
   PubMed Web of Science ®Google Scholar
• YOUNES A, AGGARWALL BB: Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. Cancer (2003) 98:458-467.
   PubMed Web of Science ®Google Scholar
• GEORGAKIS GV, LI Y, HUMPHREYS R et al.: Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br. J. Haematol. (2005) 130:501-510.
   PubMed Web of Science ®Google Scholar
• PUKAC L, KANAKARAJ P, HUMPHREYS R et al.: HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br. J. Cancer (2005) 92:1430-1441.
   PubMed Web of Science ®Google Scholar
• YOUNES A, VOSE J, ZELENETZ AD et al.: Results of a Phase II trial of HGS-ETR1 (agonisitic human monolcolanl antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin’s lymphoma (NHL). Blood (2005) 106:489.
   Google Scholar
• VAN KOOTEN C, BANCHEREAU J: CD40-CD40 ligand. J. Leukoc. Biol. (2000) 67:2-17.
   PubMed Web of Science ®Google Scholar
• YOUNES A, CARBONE A: CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders. Int. J. Biol. Markers (1999) 14:135-143.
   PubMed Web of Science ®Google Scholar
• CARBONE A, GLOGHINI A: Diagnostic significance of CD40, CD40L, and CD26 expression in Hodgkin’s disease and other lymphomas. Am. J. Clin. Pathol. (1996) 105:522-523.
   PubMedGoogle Scholar
• CARBONE A, GLOGHINI A, GRUSS HJ, PINTO A: CD40 antigen expression on Reed-Sternberg cells. A reliable diagnostic tool for Hodgkin’s disease [letter; comment]. Am. J. Pathol. (1995) 146:780-781.
   PubMed Web of Science ®Google Scholar
• KATO K, SANTANA-SAHAGAN E, RASSENTI LZ et al.: The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J. Clin. Invest. (1999) 104:947-955.
   PubMed Web of Science ®Google Scholar
• VIALLARD JF, SOLANILLA A, GAUTHIER B et al.: Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood (2002) 99:2612-2614.
   PubMedGoogle Scholar
• YOUNES A, SNELL V, CONSOLI U et al.: Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia. Br. J. Haematol. (1998) 100:135-141.
   PubMed Web of Science ®Google Scholar
• FIUMARA P, YOUNES A: CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies. Br. J. Haematol. (2001) 113:265-274.
   PubMed Web of Science ®Google Scholar
• YOUNES A: The dynamics of life and death of malignant lymphocytes. Curr. Opin. Oncol. (1999) 11:364-369.
   PubMedGoogle Scholar
• WENG W, TONG X, LUQMAN M, LEVY R: A fully human anti-CD40 antagonistic antibody, CHIR-12.12, inhibit the proliferation of human B cell non-Hodgkin lymphoma. Blood (2004) 104:3279.
   Google Scholar
• DRACHMAN JG, LAW CL, FURMAN RR et al.: A humanized anti CD40 monoclonal antibody (SGN-40) demonstrates antitumor activity in non-Hodgkin lymphoma: Initiation of a Phase I clinical trial. J. Clin. Oncol. (2005) 23:6572.
   Google Scholar
• TAI YT, CATLEY LP, MITSIADES CS et al.: Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. (2004) 64:2846-2852.
   PubMed Web of Science ®Google Scholar
• LAW CL, GORDON KA, COLLIER J et al.: Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res. (2005) 65:8331-8338.
   PubMed Web of Science ®Google Scholar
• TAI YT, LI X, TONG X et al.: Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. (2005) 65:5898-5906.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER P, TSCHOPP J: BAFF and the regulation of B cell survival. Immunol. Lett. (2003) 88:57-62.
   PubMed Web of Science ®Google Scholar
• MACKAY F, WOODCOCK SA, LAWTON P et al.: Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. (1999) 190:1697-1710.
   PubMed Web of Science ®Google Scholar
• KHARE SD, SAROSI I, XIA XZ et al.: Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc. Natl. Acad. Sci. USA (2000) 97:3370-3375.
   PubMed Web of Science ®Google Scholar
• KLEIN B, TARTE K, JOURDAN M et al.: Survival and proliferation factors of normal and malignant plasma cells. Int. J. Hematol. (2003) 78:106-113.
   PubMed Web of Science ®Google Scholar
• KOLB JP, KERN C, QUINEY C, ROMAN V, BILLARD C: Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. Curr. Drug Targets Cardiovasc. Haematol. Disord. (2003) 3:261-286.
   PubMedGoogle Scholar
• KERN C, CORNUEL JF, BILLARD C et al.: Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood (2004) 103:679-688.
   PubMed Web of Science ®Google Scholar
• NOVAK AJ, BRAM RJ, KAY NE, JELINEK DF: Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood (2002) 100:2973-2979.
   PubMed Web of Science ®Google Scholar
• MOREAUX J, LEGOUFFE E, JOURDAN E et al.: BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood (2004) 103:3148-3157.
   PubMed Web of Science ®Google Scholar
• NOVAK AJ, DARCE JR, ARENDT BK et al.: Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood (2004) 103:689-694.
   PubMed Web of Science ®Google Scholar
• HE B, CHADBURN A, JOU E, SCHATTNER EJ, KNOWLES DM, CERUTTI A: Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J. Immunol. (2004) 172:3268-3279.
   PubMed Web of Science ®Google Scholar
• RICHARDSON PG, HIDESHIMA T, ANDERSON KC: Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control (2003) 10:361-369.
   PubMedGoogle Scholar
• ADAMS J: Potential for proteasome inhibition in the treatment of cancer. Drug Discov. Today (2003) 8:307-315.
   PubMed Web of Science ®Google Scholar
• ZHENG B, GEORGAKIS GV, LI Y et al.: Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin. Cancer Res. (2004) 10:3207-3215.
   PubMed Web of Science ®Google Scholar
• O’CONNOR OA, WRIGHT J, MOSKOWITZ C et al.: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J. Clin. Oncol. (2005) 23:676-684.
   PubMed Web of Science ®Google Scholar
• GOY A, YOUNES A, MCLAUGHLIN P et al.: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol. (2005) 23:667-675.
   PubMed Web of Science ®Google Scholar
• ASSOULINE S, BELCH A, SEHN L et al.: A Phase II study of bortezomib in patients with mantle cell lymphoma. Blood (2003) 102:3358.
   Google Scholar
• BELAND JL, ADLER H, DEL-PAN NC et al.: Recombinant CD40L treatment protects allogeneic murine bone marrow transplant recipients from death caused by herpes simplex virus-1 infection. Blood (1998) 92:4472-4478.
   PubMedGoogle Scholar
• STRAUSS SJ, MAHARAJ L, STEC J et al.: Phase II clinical study of bortezomib (Velcade) in patients with relapsed/refractory non-Hodgkin lymphoma and Hodgkin disease. Blood (2004) 104:1386.
   PubMedGoogle Scholar
• GOY A, BERNSTEIN S, KAHL B et al.: Bortezomib in patients with relapsed or refractory mantle cell lymphoma: preliminary results of the PINNACLE study. J. Clin. Oncol. (2005) 23:6563.
   Google Scholar
• FRESNO VARA JA, CASADO E, DE CASTRO J, CEJAS P, BELDA-INIESTA C, GONZALEZ-BARON M: PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. (2004) 30:193-204.
   PubMed Web of Science ®Google Scholar
• LU Y, WANG H, MILLS GB: Targeting PI3K-AKT pathway for cancer therapy. Rev. Clin. Exp. Hematol. (2003) 7:205-228.
   PubMedGoogle Scholar
• ABBOTT RT, TRIPP S, PERKINS SL, ELENITOBA-JOHNSON KS, LIM MS: Analysis of the PI-3-Kinase-PTEN-AKT pathway in human lymphoma and leukemia using a cell line microarray. Mod. Pathol. (2003) 16:607-612.
   PubMed Web of Science ®Google Scholar
• XU G, ZHANG W, BERTRAM P, ZHENG XF, MCLEOD H: Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int. J. Oncol. (2004) 24:893-900.
   PubMed Web of Science ®Google Scholar
• PAEZ J, SELLERS WR: PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat. Res. (2003) 115:145-167.
   PubMedGoogle Scholar
• DUTCHER JP: Mammalian target of rapamycin (mTOR) inhibitors. Curr. Oncol. Rep. (2004) 6:111-115.
   PubMedGoogle Scholar
• HUANG S, HOUGHTON PJ: Targeting mTOR signaling for cancer therapy. Curr. Opin. Pharmacol. (2003) 3:371-377.
   PubMed Web of Science ®Google Scholar
• SAWYERS CL: Will mTOR inhibitors make it as cancer drugs? Cancer Cell (2003) 4:343-348.
   PubMed Web of Science ®Google Scholar
• GAO N, FLYNN DC, ZHANG Z et al.: G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am. J. Physiol. Cell Physiol. (2004) 287:C281-C291.
   PubMed Web of Science ®Google Scholar
• VIGNOT S, FAIVRE S, AGUIRRE D, RAYMOND E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. (2005) 16:525-537.
   PubMed Web of Science ®Google Scholar
• CHAN S: Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br. J. Cancer (2004) 91:1420-1424.
   PubMed Web of Science ®Google Scholar
• DANCEY JE: Inhibitors of the mammalian target of rapamycin. Expert Opin. Investig. Drugs (2005) 14:313-328.
   PubMed Web of Science ®Google Scholar
• WITZIG TE, GEYER SM, GHOBRIAL I et al.: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol. (2005) 23:5347-5356.
   PubMed Web of Science ®Google Scholar
• FELDMAN E, GILES F, ROBOZ G et al.: A Phase II clinical trial of AP2(3573) an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies. J. Clin. Oncol. (2005) 23:6631.
   PubMed Web of Science ®Google Scholar
• SREEDHAR AS, KALMAR E, CSERMELY P, SHEN YF: Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett. (2004) 562:11-15.
   PubMed Web of Science ®Google Scholar
• SREEDHAR AS, CSERMELY P: Heat shock proteins in the regulation of apoptosis: new strategies in tumor therapy: a comprehensive review. Pharmacol. Ther. (2004) 101:227-257.
   PubMed Web of Science ®Google Scholar
• GOETZ MP, TOFT DO, AMES MM, ERLICHMAN C: The Hsp90 chaperone complex as a novel target for cancer therapy. Ann. Oncol. (2003) 14:1169-1176.
   PubMed Web of Science ®Google Scholar
• YAMADA S, ONO T, MIZUNO A, NEMOTO TK: A hydrophobic segment within the C-terminal domain is essential for both client-binding and dimer formation of the HSP90-family molecular chaperone. Eur. J. Biochem. (2003) 270:146-154.
   PubMedGoogle Scholar
• PASSINEN S, VALKILA J, MANNINEN T, SYVALA H, YLIKOMI T: The C-terminal half of Hsp90 is responsible for its cytoplasmic localization. Eur. J. Biochem. (2001) 268:5337-5342.
   PubMedGoogle Scholar
• KAMAL A, THAO L, SENSINTAFFAR J et al.: A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature (2003) 425:407-410.
   PubMed Web of Science ®Google Scholar
• ROWLANDS MG, NEWBATT YM, PRODROMOU C, PEARL LH, WORKMAN P, AHERNE W: High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal. Biochem. (2004) 327:176-183.
   PubMed Web of Science ®Google Scholar
• WORKMAN P: Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol. Med. (2004) 10:47-51.
   PubMed Web of Science ®Google Scholar
• WORKMAN P: Overview: translating Hsp90 biology into Hsp90 drugs. Curr. Cancer Drug Targets (2003) 3:297-300.
   PubMed Web of Science ®Google Scholar
• UEHARA Y: Natural product origins of Hsp90 inhibitors. Curr. Cancer Drug Targets (2003) 3:325-330.
   PubMed Web of Science ®Google Scholar
• NECKERS L: Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification. Curr. Med. Chem. (2003) 10:733-739.
   PubMed Web of Science ®Google Scholar
• ISAACS JS, XU W, NECKERS L: Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell (2003) 3:213-217.
   PubMed Web of Science ®Google Scholar
• BAGATELL R, WHITESELL L: Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol. Cancer Ther. (2004) 3:1021-1030.
   PubMed Web of Science ®Google Scholar
• IVY PS, SCHOENFELDT M: Clinical trials referral resource. Current clinical trials of 17-AG and 17-DMAG. Oncology (2004) 18:610, 615, 619-620.
   PubMedGoogle Scholar
• CHIOSIS G, LUCAS B, HUEZO H, SOLIT D, BASSO A, ROSEN N: Development of purine-scaffold small molecule inhibitors of Hsp90. Curr. Cancer Drug Targets (2003) 3:371-376.
   PubMed Web of Science ®Google Scholar
• MONNERET C: Histone deacetylase inhibitors. Eur. J. Med. Chem. (2005) 40:1-13.
   PubMed Web of Science ®Google Scholar
• HESS-STUMPP H: Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur. J. Cell Biol. (2005) 84:109-121.
   PubMed Web of Science ®Google Scholar
• DRUMMOND DC, NOBLE CO, KIRPOTIN DB, GUO Z, SCOTT GK, BENZ CC: Clinical development of histone deacetylase inhibitors as anticancer agents. Ann. Rev Pharmacol. Toxicol. (2005) 45:495-528.
   PubMed Web of Science ®Google Scholar
• SHAO Y, GAO Z, MARKS PA, JIANG X: Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA (2004) 101:18030-18035.
   PubMed Web of Science ®Google Scholar
• SAKAJIRI S, KUMAGAI T, KAWAMATA N, SAITOH T, SAID JW, KOEFFLER HP: Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp. Hematol. (2005) 33:53-61.
   PubMed Web of Science ®Google Scholar
• MCLAUGHLIN F, LA THANGUE NB: Histone deacetylase inhibitors open new doors in cancer therapy. Biochem. Pharmacol. (2004) 68:1139-1144.
   PubMed Web of Science ®Google Scholar
• ACHARYA MR, SPARREBOOM A, VENITZ J, FIGG WD: Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol. Pharmacol. (2005) 68:917-932.
   PubMed Web of Science ®Google Scholar
• KELLY WK, RICHON VM, O’CONNOR O et al.: Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. (2003) 9:3578-3588.
   PubMed Web of Science ®Google Scholar
• KELLY WK, O’CONNOR O A, KRUG LM et al.: Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Clin. Oncol. (2005) 23:3923-3931.
   Google Scholar
• DUVIC M, TALPUR R, ZHANG C, GOY A, RICHON VM, FRANKEL SR: Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) unresponsive to conventional therapy. J. Clin. Oncol. (2005) 23:6571.
   Google Scholar
• UEDA H, MANDA T, MATSUMOTO S et al.: FR90(1228) a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J. Antibiot. (1994) 47:315-323.
   Google Scholar
• FURUMAI R, MATSUYAMA A, KOBASHI N et al.: FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. (2002) 62:4916-4921.
   PubMed Web of Science ®Google Scholar
• BYRD JC, MARCUCCI G, PARTHUN MR et al.: A Phase I and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood (2005) 105:959-967.
   PubMed Web of Science ®Google Scholar
• SANDOR V, BAKKE S, ROBEY RW et al.: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR90(1228) NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. (2002) 8:718-728.
   PubMed Web of Science ®Google Scholar
• MARSHALL JL, RIZVI N, KAUH J et al.: A Phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Exp. Ther. Oncol. (2002) 2:325-332.
   PubMedGoogle Scholar
• PIEKARZ R, FRYE R, TURNER M et al.: Update on the Phase II trial and correlative studies of depsipeptide in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. J. Clin. Oncol. (2004) 22:3028.
   Google Scholar
• YE BH, LISTA F, LO COCO F et al.: Alterations of a zinc finger-encoding gene, Bcl-6, in diffuse large-cell lymphoma. Science (1993) 262:747-750.
   PubMed Web of Science ®Google Scholar
• YE BH, RAO PH, CHAGANTI RS, DALLA-FAVERA R: Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma. Cancer Res. (1993) 53:2732-2735.
   PubMed Web of Science ®Google Scholar
• LO COCO F, YE BH, LISTA F et al.: Rearrangements of the Bcl6 gene in diffuse large cell non-Hodgkin’s lymphoma. Blood (1994) 83:1757-1759.
   PubMedGoogle Scholar
• PHAN RT, SAITO M, BASSO K, NIU H, DALLA-FAVERA R: Bcl6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat. Immunol. (2005) 6:1054-1060.
   PubMed Web of Science ®Google Scholar
• PHAN RT, DALLA-FAVERA R: The Bcl6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature (2004) 432:635-639.
   PubMed Web of Science ®Google Scholar
• YE BH, CATTORETTI G, SHEN Q et al.: The Bcl-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat. Genet. (1997) 16:161-170.
   PubMed Web of Science ®Google Scholar
• CATTORETTI G, PASQUALUCCI L, BALLON G et al.: Deregulated Bcl6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell (2005) 7:445-455.
   PubMed Web of Science ®Google Scholar
• POLO JM, DELL’OSO T, RANUNCOLO SM et al.: Specific peptide interference reveals Bcl6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat. Med. (2004) 10:1329-1335.
   PubMed Web of Science ®Google Scholar
• MARUMOTO T, ZHANG D, SAYA H: Aurora A – a guardian of poles. Nat. Rev. Cancer (2005) 5:42-50.
   PubMed Web of Science ®Google Scholar
• VAN VUGT MA, MEDEMA RH: Polo-like kinase-1: activity measurement and RNAi-mediated knockdown. Methods Mol. Biol. (2005) 296:355-369.
   PubMedGoogle Scholar
• BENSON C, KAYE S, WORKMAN P, GARRETT M, WALTON M, DE BONO J: Clinical anticancer drug development: targeting the cyclin-dependent kinases. Br. J. Cancer (2005) 92:7-12.
   PubMed Web of Science ®Google Scholar
• HAMADA M, YAKUSHIJIN Y, OHTSUKA M, KAKIMOTO M, YASUKAWA M, FUJITA S: Aurora2/BTAK/STK15 is involved in cell cycle checkpoint and cell survival of aggressive non-Hodgkin’s lymphoma. Br. J. Haematol. (2003) 121:439-447.
   PubMed Web of Science ®Google Scholar
• DITCHFIELD C, JOHNSON VL, TIGHE A et al.: Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell Biol. (2003) 161:267-280.
   PubMed Web of Science ®Google Scholar
• SESSA F, MAPELLI M, CIFERRI C et al.: Mechanism of Aurora B activation by INCENP and inhibition by hesperadin. Mol. Cell (2005) 18:379-391.
   PubMed Web of Science ®Google Scholar
• MORROW CJ, TIGHE A, JOHNSON VL, SCOTT MI, DITCHFIELD C, TAYLOR SS: Bub1 and aurora B cooperate to maintain BubR1-mediated inhibition of APC/CCdc20. J. Cell Sci. (2005) 118:3639-3652.
   PubMed Web of Science ®Google Scholar
• GADEA BB, RUDERMAN JV: Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts. Mol. Biol. Cell (2005) 16:1305-1318.
   PubMed Web of Science ®Google Scholar
• HARRINGTON EA, BEBBINGTON D, MOORE J et al.: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. (2004) 10:262-267.
   PubMed Web of Science ®Google Scholar
• HAUF S, COLE RW, LATERRA S et al.: The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J. Cell Biol. (2003) 161:281-294.
   PubMed Web of Science ®Google Scholar
• LOWERY DM, LIM D, YAFFE MB: Structure and function of Polo-like kinases. Oncogene (2005) 24:248-259.
   PubMed Web of Science ®Google Scholar
• WINKLES JA, ALBERTS GF: Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene (2005) 24:260-266.
   PubMed Web of Science ®Google Scholar
• MITO K, KASHIMA K, KIKUCHI H, DAA T, NAKAYAMA I, YOKOYAMA S: Expression of Polo-Like Kinase (PLK1) in non-Hodgkin’s lymphomas. Leuk. Lymphoma (2005) 46:225-231.
   PubMed Web of Science ®Google Scholar
• SYED N, SMITH P, SULLIVAN A et al.: Transcriptional silencing of Polo-like kinase 2 (Snk/Plk2) is a frequent event in B cell malignancies. Blood (2006) 107:250-256.
   PubMed Web of Science ®Google Scholar
• ECKERDT F, YUAN J, STREBHARDT K: Polo-like kinases and oncogenesis. Oncogene (2005) 24:267-276.
   PubMed Web of Science ®Google Scholar
• LIN TS, HOWARD OM, NEUBERG DS, KIM HH, SHIPP MA: Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leuk. Lymphoma (2002) 43:793-797.
   PubMed Web of Science ®Google Scholar
• BYRD JC, PETERSON BL, GABRILOVE J et al.: Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin. Cancer Res. (2005) 11:4176-4181.
   PubMed Web of Science ®Google Scholar
• SAUSVILLE EA, ARBUCK SG, MESSMANN R et al.: Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J. Clin. Oncol. (2001) 19:2319-2333.
   PubMed Web of Science ®Google Scholar
• GUO B, SU TT, RAWLINGS DJ: Protein kinase C family functions in B-cell activation. Curr. Opin. Immunol. (2004) 16:367-373.
   PubMed Web of Science ®Google Scholar
• SHIPP MA, ROSS KN, TAMAYO P et al.: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. (2002) 8:68-74.
   PubMed Web of Science ®Google Scholar
• HANS CP, WEISENBURGER DD, GREINER TC et al.: Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod. Pathol. (2005) 18:1377-1384.
   PubMed Web of Science ®Google Scholar
• SU TT, GUO B, KAWAKAMI Y et al.: PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat. Immun. (2002) 3:780-786.
   Google Scholar
• FERRARA N, GERBER HP, LECOUTER J: The biology of VEGF and its receptors. Nat. Med. (2003) 9:669-676.
   PubMed Web of Science ®Google Scholar
• PLATE K: From angiogenesis to lymphangiogenesis. Nat. Med. (2001) 7:151-152.
   PubMed Web of Science ®Google Scholar
• OLOFSSON B, KORPELAINEN E, PEPPER MS et al.: Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc. Natl. Acad. Sci. USA (1998) 95:11709-11714.
   PubMed Web of Science ®Google Scholar
• RIBATTI D, VACCA A, BERTOSSI M, DE BENEDICTIS G, RONCALI L, DAMMACCO F: Angiogenesis induced by B-cell non-Hodgkin’s lymphomas. Lack of correlation with tumor malignancy and immunologic phenotype. Anti-Cancer Res. (1990) 10:401-406.
   PubMed Web of Science ®Google Scholar
• RIBATTI D, VACCA A, MARZULLO A et al.: Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin’s lymphomas. Int. J. Cancer (2000) 85:171-175.
   PubMed Web of Science ®Google Scholar
• VACCA A, RIBATTI D, RONCALI L, DAMMACCO F: Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Leuk. Lymphoma (1995) 20:27-38.
   PubMed Web of Science ®Google Scholar
• SALVEN P, ORPANA A, TEERENHOVI L, JOENSUU H: Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood (2000) 96:3712-3718.
   PubMed Web of Science ®Google Scholar
• STOPECK AT, BELLAMY W, UNGER J et al.: Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin’s lymphoma (NHL): Southwest Oncology Group Study S0108. J. Clin. Oncol. (2005) 23:6529.
   Google Scholar
• PRO B, YOUNES A, ALBITAR M et al.: Thalidomide for patients with recurrent lymphoma. Cancer (2004) 100:1186-1189.
   PubMed Web of Science ®Google Scholar
• DRACH J, KAUFMANN H, PUESPOEK A et al.: Marked anti-tumor activity of rituximab plus thalidomide in patients with relapsed/resistant mantle cell lymphoma. Blood (2002) 100:606.
   Google Scholar
• YEE K, O’BRIEN S, WIERDA W et al.: A Phase I/II study of the oral mTOR inhibitor RAD001 in patients with advanced hematologic malignancies. J. Immunother. (2004) 27:S35-S35.
   Web of Science ®Google Scholar